Article

Sydney Morning HeraldSydney Morning Herald on 2019-12-29 14:00

Heart-stopper: CSL's $800m heart attack trial

As far as investments go, CSL Limited's $800 million all-or-nothing bet on a treatment to stop recurrent cardiovascular events is a heart-stopper.

Related news